SavedAdd your journal

Journals / The European Research Journal / 2019 / Cilt: 5 - Sayı: 4

Investigation of effects of neurotrophic factors on painful diabetic neuropathy: an experimental study

FARUK KILINÇ
Ramis ÇOLAK
Mete ÖZCAN
Ahmet AYAR
Pages
641–648
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

However, there is a need for larger-scale and longer-term studies for clinical use.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: We have studied the effects of neurotrophin-4 (NT-4) different doses on the pain levels of streptozocin-induced diabetic rats.
📊
Key Findings & Data:Methods: Thirty-five 3-week-old male rats were used.
💡
Conclusion & Impact:However, there is a need for larger-scale and longer-term studies for clinical use.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Diabetic neuropathy · hot plate · neurotrophin-4

Abstract

Objective: We have studied the effects of neurotrophin-4 (NT-4) different doses on the pain levels of streptozocin-induced diabetic rats. Methods: Thirty-five 3-week-old male rats were used. After induction of diabetes in rats with streptozocin (nearly 4 weeks); diabetic animals were divided into 4 groups. The first group; healthy control group (n = 15 ), the second group; diabetic control group ( n = 10 ), the third group; low dose (0.3 mg/ kg ) recombinant human NT-4 was applied ( n = 4 ) and the fourth group; high dose recombinant human NT-4 was applied (n = 6). Results: In the low-dose NT-4 group, the pain threshold values did not differ from the diabetic control and healthy control groups. In the high dose NT-4 group, a rise was observed in the pain threshold values of hot plate in comparison with the healthy control group, diabetic control group and low dose applied group and this rise reached at the level of statistical significance (p < 0.05). Conclusion: Neurotrophic factors (neurotrophin-4) have been shown to be effective on painful diabetic neuropathy in streptozocin-induced diabetic rats. However, there is a need for larger-scale and longer-term studies for clinical use.

🔖

Cite This Article

KILINÇ, F., ÇOLAK, R., ÖZCAN, M., AYAR, A. (2019). Investigation of effects of neurotrophic factors on painful diabetic neuropathy: an experimental study. The European Research Journal, Cilt: 5 - Sayı: 4, 641–648. https://ajindex.com/articles/361213

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (18)

  1. Chawla A, Chawla R, Jaggi S. Microvasular and macrovascular complications in diabetes mellitus: Distinct or continuum. Indian J Endocrinol Metab 2016;20:546-51
  2. Davon A. M, Chronic pain. A primary Care Guide to Practical Management, second ed., Human Pres: Totawa, NJ. 2005;114-5
  3. Price RD, Milne SA, Sharkey J, Matsuoka N, Advances in small molecules promoting neurotrophic function. Pharmacol Ther 2007;115:292-306
  4. Bennett DL. Neurotrophic factors important regulators of nociceptive function. Neuroscientist 2001;7:13-7
  5. Skaper SD. The neurotrophin family of neurotrophic factors: an overview. Methods Mol Biol 2012;846:1-12
  6. Kerr BJ, Bradbury EJ, Bennett DL, Trivedi PM, Dassan P, French J, et al. Brain-derived neurotrophic factor modulates nociceptive sensory inputs and NMDA-evoked responses in the rat spinal cord. J Neurosci 1999;19:5138-48
  7. Chen SQ, Cai Q, Shen YY, Cai XY, Lei HY. Combined use of NGF/BDNF/bFGF promotes proliferation and differentiation of neural stem cells in vitro. Int J Dev Neurosci 2014;38:74-8
  8. Christianson JA, Ryals JM, McCarson KE, Wright DE. Beneficial actions of neurotrophin therapy on diabetes-induced hypoalgesia in mice. J Pain 2003;4:493-504
  9. Christianson JA, Ryals JM, Johnson MS, Dobrowsky RT, Wright DE. Neurotrophic modulation of myelinated cutaneous innervation and mechanical sensory loss in diabetic mice. Neuroscience 2007;145:303-13
  10. Handwerker HO, Kobal G. Psychophysiology of experimentally induced pain. Physiol Rev 1993;73:639-71
  11. Deli G, Bosecyak E, Pusch G, Komoly S, Feher G. Diabetic neuropathies: diagnosis and management. Neuroendocrinology 2013;98:267-80
  12. Vinik AI, Park TS, Stansberry K B, Pittenger GL. Diabetic neuropathies. Diabetologia 2000;43;957-73
  13. Callaghan BC, Cheng HT, Stables CL, Smith AL, Feldman EL. Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurol 2002;11:521-34
  14. Rees DA, Alcolado JC. Animal models of diabetes mellitus. Diabet Med 2005;22:359-70
  15. Malik RA. Current and future strategies for the management of diabetic neuropathy. Treat Endocrinol 2003;2:389-400
  16. Ahlgren SC, Levine JD. Mechanical hyperlgesia in streptozocin diabetic rat is not sympathetically maintained. Brain Res 1993;616:171-5
  17. Ahlgren SC, White DM, Levine JD. Increased responsiveness of sensory neurons in the saphenous nerve of the streptozotocin-diabetic rat. J Neurophysiol 1992;68:2077-85
  18. Piercy V, Banner SE, Bhattacharyya